Background and methods: In our previous analyses, we found significantly lower levels of growth hormone receptor (GHR) mRNA in adipose tissues of obese than in those of lean individuals, suggesting that idiopathic obesity involves GH resistance due to decreased GHR availability. To understand the mechanism(s) behind this downregulation, we performed an in silico analysis of the three most relevant GHR gene promoters, which revealed putative response elements (REs) for a number of obesity adiposeassociated factors, including tumor necrosis factor-alpha (TNFa), hypoxia-inducible factor-1-alpha (HIF-1a) and glucocorticoids. We then characterized the dose-dependent effects of these factors on GHR expression in HEK293 cells and in mature human SGBS (Simpson-Golabi-Behmel syndrome) adipocytes using quantitative reverse transcriptase-PCR and assessed the function of their putative REs by luciferase-reporter assays, site-directed mutagenesis and chromatin immunoprecipitation (ChIP) assays. Results: TNFa treatments significantly reduced GHR mRNA levels and GHR promoter activities at doses X10 ng ml À1 in both cell lines. Transient overexpression of HIF-1a or exposure to the hypoxia mimetic CoCl 2 significantly increased GHR mRNA levels and promoter activities. Dexamethasone had biphasic effects: there was a significant increase in GHR mRNA levels at 10 À10 M and in promoter activities at 10 À10 and 10 À8 M, whereas a significant decrease in both mRNA levels and promoter activities occurred at 10 À6 M. Site-directed mutagenesis of the putative nuclear factor-kB, HIF-1a and glucocorticoid REs resulted in the loss of these effects, whereas ChIP analysis confirmed specific transcription factor-promoter interactions. Conclusions: Our results suggest that the increased activity of TNFa, HIF-1a and glucocorticoids in obese adipose tissues could alter GHR gene transcription through specific REs and that TNFa may be involved in the development of GH resistance.
Introduction
Normal growth of body fat mass occurs as hormonal and nutritional cues promote adipocyte hyperplasia (adipogenesis) and hypertrophy (increasing cellular lipogenesis and lipid accumulation in adipocytes). [1] [2] [3] However, with extreme adiposity, as in obesity, adipose tissue function is severely altered. As fat tissue mass increases, there is a reduction in oxygen diffusion into cells. [4] [5] [6] [7] [8] This can create pockets of hypoxia marked by cells expressing increased levels of the transcription factor, hypoxia-inducible factor-1-alpha (HIF-1a). 9 Other characteristic features of obesity include increased adipose tissue levels of proinflammatory factors, such as tumor necrosis factor-alpha (TNFa), 10 due to increased macrophage infiltration into this tissue, and increased intracellular cortisol levels due to altered expression and activity of the enzymes 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) and 2 (11b-HSD2).
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The adipose tissue is one of the major targets of growth hormone (GH) action: GH receptors (GHRs) are abundantly expressed and GH has profound effects on adipogenesis, lipogenesis and lipolysis. [14] [15] [16] Despite positive effects of GH treatments on the reduction of fat mass in individuals with endocrinopathy-related obesity, GH treatments in individuals with idiopathic obesity are generally ineffective. 17 In our previous analysis, we found, for the first time, significantly lower GHR mRNA levels in the omental and subcutaneous fat depots of obese compared to lean individuals (Erman et al., in press). These data suggest that GH insensitivity in obesity may result from decreased GHR availability and that this phenomenon is an important component of obesity-related adiposopathy.
The human GHR gene is found on chromosome 5p13.1-p12 and its expression in various tissues is influenced by hormones, nutritional status 18 and developmental processes. [19] [20] [21] A total of 14 different GHR mRNA variants (V1-V5, V7-V9 and VA-VE) with different 5 0 -untranslated regions exist, all of which code for the same protein. These variant mRNAs arise as a result of the use of different promoters together with alternative splicing and display developmental and tissue-specific expression profiles: while V2, V3, V5, V9 and VA-VE mRNAs are expressed ubiquitously, the others are postnatal liver specific. 19, 20, 22 There is a marked increase in total GHR expression during murine and human pre-adipocyte differentiation. 19, 23 Of the different GHR mRNA variants, V2, V3 and V9 are the most highly expressed in human adipocytes; V2 is the predominant variant, accounting for 80-90% of total hGHR mRNA in these cells. 19 To understand the mechanism(s) behind the decrease in adipocyte hGHR expression with obesity, we performed an in silico analysis of the promoter regions of V2, V3 and V9 using MatInspector (http://www.genomatix.de/en/index.html) and found a number of putative response elements (REs) for factors present in adipose tissue during obesity (Figure 1 ). These include sites for nuclear factor kappa B (NFkB-RE), which acts downstream of TNFa signaling, as well as for HIF-1a (HRE) and glucocorticoids (GRE).
We then assessed the dose-dependent actions of TNFa, HIF-1a and the synthetic glucocorticoid, dexamethasone (Dex), on GHR mRNA expression in HEK293 cells and in mature SGBS (Simpson-Golabi-Behmel syndrome) human adipocytes 19, 24 to determine whether they might be involved in the obesity-associated decrease in GHR expression. We further assessed the functionality of these putative REs through luciferase-promoter assays, site-directed mutagenesis and chromatin immunoprecipitation (ChIP) assays. Our data show that TNFa, HIF-1a and glucocorticoids can alter human GHR gene transcription in both human adipocytes and HEK293 cells by interacting with specific REs. We observed that, although glucocorticoids have the expected dose-dependent biphasic effects, HIF-1a significantly upregulates GHR expression. The latter finding suggests that GHR is a hypoxia-inducible gene and may be involved in hypoxia-induced processes such as angiogenesis and tumorigenesis in which components of the GH/(insulinlike growth factor) IGF axis have been implicated. In contrast, TNFa leads to a significant downregulation of the GHR gene. These data implicate the proinflammatory cytokine as a major factor, that decreases GHR availability in adipose tissues during obesity and possibly in other tissues during inflammation.
Materials and methods
Cell culture HEK293 cells (American Type Culture Collection, Bethesda, MD, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Burlington, ON, Canada) supplemented with 10% fetal bovine serum, 25 mM HEPES, 100 IU ml À1 penicillin G and 1.6 mg ml À1 gentamycin.
Human SGBS pre-adipocytes, which were originally derived from the stromal cell fraction of subcutaneous adipose tissue obtained from an infant with SGBS, 24 were cultured in DMEM/F12 (Invitrogen) supplemented with 10% fetal bovine serum (non-heat inactivated), 33 mM biotin (Sigma, Mississauga, ON, Canada; B-4639), 17 mM pantothenate (Sigma; P-5155), 100 IU ml À1 penicillin G and 1.6 mg ml
À1
gentamycin. All cells were incubated at 37 1C in 5% CO 2 in air.
SGBS differentiation SGBS cells were grown in serum-containing media until full confluency, after which they were grown for 4 days in serumfree DMEM/F12 supplemented with 33 mM biotin, 17 mM pantothenate, 100 IU ml À1 penicillin G, 1.6 mg ml À1 gentamycin, 0.01 mg ml À1 human transferrin (Sigma; T-5391), . RNA was extracted from HEK293 cells using Trizol (Invitrogen), whereas RNA from mature SGBS cells was isolated using the RNeasy RNA extraction kit (Qiagen, Mississauga, ON, Canada). RNA (1 mg) was reverse transcribed using the QuantiTect Reverse Transcription kit (Qiagen). The QuantiFast SYBR Green PCR kit (Qiagen) was used for quantitative PCR. The cDNA product (2.5 ml) was amplified in duplicate with primers purchased from Qiagen for total hGHR (exons 6/7) and b-actin. Normalization and quantification were performed using the comparative Ct method. Data are expressed as fold change (2 ÀDDCt ) relative to b-actin.
Regulation of human GHR in obesity
Transient transfection and reporter gene assay HEK293 cells (1 Â 10
À5
) were seeded in 12-well plates and grown to 40-60% confluency. Transfections were performed using Polyfect (Qiagen). Each well was transfected with either 0.5 mg GHR-reporter constructs in a pA 3 at room temperature. For the b-galactosidase assay, 10 ml of the lysates was dispensed into a 96-well microtiter plate and incubated for 1 h at room temperature in the dark along with 100 ml b-galactosidase solution (0.1 mM b-galactosidase substrate in 100 mM sodium phosphate (pH 7.5), 1 mM MgCl 2 and 5% Sapphire II Enhancer (Tropix Galactonstar, Bedford, MA, USA)). For the luciferase assay, 100 ml of the lysates was dispensed into a 96-well microtiter plate and luminescence activity was assayed with 1 Â luciferin solution (0.1 mM coenzyme A, 2.5 mM ATP, 1 Â luciferin, 5 mM MgCl 2 and 500 mM Tris-HCl (pH 7.9)); measurements were taken using a bioluminometer (GloMax; Promega Corporation). Experiments were performed in triplicates. Data are expressed as a ratio of luciferase activity over b-galactosidase activity and normalized to the empty pA 3 Luc vector data.
Site-directed mutagenesis
Mutations were introduced into the V3P3 pA 3 Luc-reporter construct with forward and reverse primers carrying the desired mutations for the HRE, GRE and NFkB-REs (Table 1) , using the QuickChange Lightning Site-directed Mutagenesis kit (Stratagene, La Jolla, CA, USA). The presence of mutations was confirmed by sequencing analysis (Applied Biosystems, Mississauga, ON, Canada).
Chromatin immunoprecipitation assay HEK293 cells were grown in 100 mm dishes and treated with TNFa or Dex for 1 h. For HIF-1a experiments, cells were first transfected with 2 mg pcDNA3-HA-HIF-1a, and 24 h after transfection, cells were treated with 100 mM cobalt chloride (0.1 M CoCl 2 ; Sigma 15826) for 24 h to reduce HIF-1a degradation. Cells were then washed two times with 1 Â phosphate-buffered saline, cross-linked using DMEM with 1% formaldehyde (ICN Biomedicals Inc., Aurora, OH, USA) for 10 min at room temperature, washed with cold 1 Â phosphate-buffered saline, scraped into 1 ml phosphatebuffered saline and centrifuged. The pellet was dissolved in 300 ml SDS lysis buffer (1% SDS, 10 mM EDTA and 50 mm TrisHCl (pH 8.1)) supplemented with 1 Â protease inhibitors (Roche, Mississauga, ON, Canada). The lysates were Regulation of human GHR in obesity A Erman et al sonicated (VibraCell Sonicator, Sonics, Betatek Inc., Toronto, ON, Canada) at 50% amplitude 6 times for 15 s with a 1-min incubation on ice in between. The lysate was then diluted 10 Â with ChIP dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl and 20 mM Tris-HCl (pH 8.1) with 1 Â protease inhibitors). A volume of 500 ml of this solution was kept frozen as INPUT, whereas the remaining lysate was divided into 1 ml aliquots and pre-cleared for 1 h at 4 1C using 45ml of 50% protein A/G-agarose beads (sc-2003; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), 2 mg bovine serum albumin (NEB, Beverly, MA, USA) and 4 mg degraded herring sperm DNA (Sigma). Supernatants were immunoprecipitated for 3 h at 4 1C with either 4-10 mg of specific antibodies purchased from Santa Cruz Biotechnology Inc. against NFkB subunits p50 (goat polyclonal, sc-1190X) and p65 (rabbit polyclonal, sc-109X) or against the glucocorticoid receptor (rabbit polyclonal, sc-8992X). HIF-1a antibody (mouse monoclonal, NB100-134) was purchased from Novus Biologicals (Littleton, CO, USA). Control samples were immunoprecipitated with 4-10 mg of IgG from goat (sc-2028), rabbit (sc-2027) or mouse (sc-2025). The complexes were pulled down by incubating overnight at 4 1C with 45 ml of 50% protein A/G-agarose beads, 2 mg bovine serum albumin and 4 mg degraded herring sperm DNA. Beads were collected and washed sequentially for 5 min each with 1 ml of low-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA and 20 mM Tris-HCl (pH 8.1)), high-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl and 20 mM Tris-HCl (pH 8.1)), LiCl buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate (Na salt), 1 mM EDTA and 10 mM Tris-HCl (pH 8.1)) and TE buffer (10 mM Tris-HCl (pH 8.1) and 1 mM EDTA), followed by two extractions with 250 ml of freshly prepared extraction buffer (1% SDS, 0.1 M NaHCO 3 ). A volume of 500 ml of final eluates was reverse cross-linked overnight with 20 ml of 5 M NaCl at 65 1C along with the INPUT. Eluates were then purified using the QIAquick PCR Purification kit (Qiagen) following the manufacturer's instructions. In all, 5 ml of template DNA was amplified by PCR using Taq polymerase (Invitrogen) and primers designed to amplify the respective RE and control sites ( Table 2) . PCR products were then analyzed on a 1.3% agarose gel stained with ethidium bromide.
Results
Effects of TNFa on GHR mRNA expression and promoter activity Treatments with the proinflammatory cytokine TNFa at concentrations of X10 ng ml À1 led to a significant downregulation of GHR mRNA levels in both HEK293 and mature SGBS adipocytes (Pp0. 01) (Figure 2a) . The effects were more dramatic in mature SGBS adipocytes in which TNFa levels of 10 ng ml À1 were sufficient to induce a 78% loss of GHR mRNA expression. Consistent with these effects at the mRNA level, TNFa treatments significantly inhibited both V2V3P2 and V3P3 GHR promoter activities at doses X10 ng ml À1 (Pp0.05-0.001) (Figures 2b and c) . Although the V3P3 single NFkB site was shown to be functional by mutation analysis (Figure 2c ), the larger V2V3P2 promoter had a more marked decrease in activity (Figure 2b ), suggesting that the additional putative NFkB-RE in this promoter region is also functional. ChIP analysis of the putative NFkB sites on the V3 and V9 exons confirmed TNFa-induced binding of p50 and p65 subunits of NFkB to these regions (Figure 2d ). PCR amplification of a control region of the GHR promoter (1776-2166 bp upstream of the target area on the V3 exon) that is devoid of NFkB sites did not amplify any DNA fragments.
Effects of HIF-1a on GHR mRNA expression and promoter activity Overexpression of HIF-1a significantly upregulated GHR mRNA expression in both HEK293 and mature SGBS adipocytes (Pp0.01) (Figure 3a) . In HEK293 cells, GHR mRNA was upregulated 2.3-fold after transfection with 100 ng of a HIF-1a expression vector, whereas a similar increase was observed in SGBS adipocytes when transfected with 200 ng, suggesting that HEK293 cells are more responsive than adipocytes.
We compared the effect of HIF-1a expression on the V2V3P2 GHR promoter, which contains three putative HREs, and on the V3P3 promoter, with only one putative HRE (Figure 1 ). HIF-1a expression increased both promoter activities in agreement with the mRNA data (Figures 3b  and c) . There was a highly significant increase in V2V3P2 promoter activity in cells transfected with 200-300 ng of the HIF-1a expression vector (6-9-fold; Pp0.05, Pp0.001). HIF-1a had stimulatory effects on the smaller V3P3 promoter vector at levels of 100-200 ng (1.9-fold; Pp0.05), but the lower fold response suggests that upstream HREs are also functional. Site-directed mutagenesis of the putative HRE site on the V3P3 promoter construct completely eliminated HIF-1a-stimulatory effects (Figure 3c ). ChIP analysis demonstrated an association between HIF-1a and the putative V3, Regulation of human GHR in obesity A Erman et al as well as V9 HRE sites but not the putative site on the V2 exon following HIF-1a overexpression and treatment with the hypoxia mimetic agent, CoCl 2 (which stabilizes the HIF-1a protein) (Figure 3d ). PCR amplification of a control GHR promoter region (1776-2166 bp upstream of the target area on the V3 exon) devoid of HRE sites did not amplify any DNA product.
Effects of TNFa and hypoxia on GHR mRNA expression and promoter activity
To understand the regulation of GHR promoters in a cell exposed to both hypoxia and inflammation (obese-like state), we treated HEK293 cells simultaneously with TNFa (20 ng ml
À1
) and the hypoxia mimetic reagent, CoCl 2 (100 mM) and assessed GHR mRNA expression (Figure 3e ). Although CoCl 2 treatments alone resulted in a significant 4.5-fold increase in GHR mRNA expression (Pp0.05), when cells were simultaneously exposed to CoCl 2 and TNFa for 24 h, there was a complete loss of CoCl 2 effects (Pp0.05), demonstrating that TNFa is a very potent suppressor of GHR gene transcription.
We additionally assessed the effects of simultaneous TNFa and CoCl 2 treatments (24 h) on GHR promoter activities (Figure 3f ). We found that CoCl 2 treatment alone significantly increased both V2V3P2 and V3P3 promoter activity (Pp0.01) but not the V3P3-HRE mutant. However, when cells were treated simultaneously with CoCl 2 and TNFa, there was a significant reduction in promoter activities of all three constructs tested relative to CoCl 2 treatments (Pp0.01). Both the V3P3 and the V3P3-HRE mutant promoters, but not the V2V3P2 promoter, displayed significant decreases in activity relative to controls (Pp0.05). These data suggest that the suppressive effects of TNFa can overcome the stimulatory effects of hypoxia on GHR expression.
Effects of Dex on GHR mRNA expression and promoter activity Dex had biphasic stimulatory effects on GHR mRNA expression in both mature SGBS and HEK293 cells (Figure 4a ): there was a significant increase at 10 À10 M (Pp0.05), followed by a significant reduction at 10 À6 M (Pp0.01 vs 10
There was a similar biphasic stimulation of both the V2V3P2 and the V3P3 GHR promoter-reporter constructs by Dex (Figures 4b and c) . A significant increase in V2V3P2 promoter activity was observed at 10 À8 M (Pp0.01), followed by a significant decrease at 10 À6 M (Pp0.05 vs 10
The smaller V3P3 promoter activity displayed significant increases at 10 À10 and 10 À8 M (Pp0.05) and a significant Regulation of human GHR in obesity A Erman et al decrease at 10 À6 M (Pp0.001 vs 10 À8 M). Site-directed mutagenesis of the putative GRE on the V3P3 promoter construct resulted in the loss of stimulatory effects, suggesting that the effects of Dex on V3P3 promoter activity are mediated by this GRE (Figure 4c ). In vivo binding of glucocorticoid receptor to the putative GRE was further confirmed by ChIP analysis in which 1 h treatment with 10 À6 M Dex resulted in glucocorticoid receptor association with V3-GRE (Figure 4d ). PCR amplification of a control region devoid of GREs (1776-2166 kb upstream of the target area on the V3 exon) did not amplify a DNA product. This suggests that Dex can directly influence GHR expression by this site.
It should be noted that there are no data on the physiological concentrations of TNFa or HIF-1a in adipose tissues. The treatments that we used were based on previously published in vitro studies.
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Discussion
In our previous analysis of GHR mRNA levels in human adipose tissues, we found significantly lower GHR expression in obese than in lean individuals (Erman et al., in press). In this study, we assessed the effects of certain Regulation of human GHR in obesity A Erman et al obesity-associated factors (TNFa, HIF-1a and glucocorticoids) on GHR mRNA expression in HEK293 cells and mature human SGBS adipocytes. We also characterized the mechanisms by which these factors alter GHR expression by luciferase-promoter assays, site-directed mutagenesis of putative REs and ChIP assays to look at transcription factor-promoter interactions.
Effects of TNFa on GHR expression
In obesity, increased adipose TNFa levels are strongly implicated in altering normal adipose tissue function. Previous studies have shown that TNFa inhibits both adipogenesis and expression of genes involved in insulin signaling, leading to the development of insulin resistance. 28, 29 Our data show, for the first time, that TNFa may also be involved in obesity-associated downregulation of GHR. TNFa significantly downregulated GHR mRNA expression in both HEK293 and mature human SGBS adipocytes. This effect likely involves the specific association of NFkB subunits (p50 and p65) with two NFkB sites located in the V3 and V9 5 0 -untranslated region exons of the GHR gene. Site-directed mutagenesis of the V3 NFkB site diminished the effects of TNFa on GHR promoter activity, whereas ChIP assays showed binding to both sites suggesting that both are functional. These studies highlight a mechanism by which TNFa can regulate GHR gene transcription.
Two previous studies have shown that TNFa has effects on GHR expression in the mouse. Murine hepatocyte GHR mRNA levels decreased after exposure of cells to 10 ng ml À1 TNFa; the mechanisms involved inhibition of Sp1 and Sp3 binding to the GHR promoter. 27, 30 In addition, neutralization of TNFa in experimental models of murine colitis led to increased GHR abundance in the colon in parallel with significant reductions in nuclear NFkB (p65) levels. 31 These data suggest that increased local tissue TNFa levels in obesity and in other clinical conditions associated with TNFa excess (such as sepsis, inflammatory bowel disease, chronic liver disease, osteoporosis and rheumatoid arthritis, colitis) may lead to tissue-specific suppression of GHR expression.
Effects of HIF-1a on GHR expression
Obesity is associated with increased adipose tissue hypoxia. This study shows that GHR is a hypoxia-responsive gene: HIF-1a overexpression in mature human adipocytes and in HEK293 cells led to a significant increase in human GHR mRNA expression and promoter activities. Similar effects were observed in HEK293 cells treated with the hypoxia mimetic CoCl 2 . Mutagenesis of the putative HRE site on the Regulation of human GHR in obesity A Erman et al V3 exon eliminated this stimulatory effect, and ChIP experiments demonstrated that the two HRE sites on the V3 and V9 5 0 -untranslated region exons associate with HIF-1a transcription factor after stimulation, suggesting that the stimulatory effect of HIFs is directly mediated by functional REs on the GHR promoter.
Hypoxia is observed during normal developmental processes (such as embryogenesis, placental development), during postnatal physiological events (such as exercise, exposure to high altitudes) and during pathological states (such as ischemic disease, cancer and obesity). 4, 5, [32] [33] [34] In response to hypoxia, HIFs promote the expression of genes involved in angiogenesis, including vascular endothelial growth factor. Studies of ischemia-induced neovascularization in retinopathy have shown that local tissue GH and IGF1 have critical roles in vascularization independently of vascular endothelial growth factor activity. 35 Our finding that HIF-1a upregulates GHR expression suggests that this mechanism may contribute to vascularization, by increasing GH sensitivity and local tissue IGF-1 production in tissues directly affected by hypoxia. As HIF-1a has stimulatory effects on GHR transcription, HIF-1a activity alone does not explain the downregulation of GHR mRNA levels with obesity (Erman et al., in press). However, we also observed that the repressive effects of the proinflammatory factor TNFa can overcome the stimulatory effects of hypoxia on GHR mRNA expression and promoter activity when cells are simultaneously treated with both factors. This suggests that, as inflammatory conditions develop in fat tissue, inhibition of GHR expression will prevail. Erythropoietin (EPO), another HIF-1a stimulated gene, is also downregulated by TNFa by NFkB activation. 36, 37 This effect has been attributed to the competition between NFkB and other transcription factors for the cofactor p300-CREB-binding protein complex, which is necessary for HIF activity. 38 Effects of glucocorticoids on GHR expression Although there are no changes in circulating cortisol levels in idiopathic obesity, several studies suggest that there are increased intracellular cortisol concentrations in adipose tissues of obese vs lean individuals. 12, 39, 40 Intracellular cortisol bioavailability is controlled by 'pre-receptor ligand metabolism' that involves the enzyme 11b-HSD1, a bidirectional enzyme that catalyses the conversion of inactive cortisone to cortisol, and 11b-HSD2, which has the reverse effect. Adipocytes from obese people have elevations in 11b-HSD1 and reductions in 11b-HSD2 expression and activity, 11, 12, 41 suggesting that changes in these key enzymes are altering adipose tissue cortisol levels. Glucocorticoids are well known to exert multiple effects on the GH/IGF-1 axis: clinical investigations have clearly shown that long-term high-dose glucocorticoid treatments lead to growth failure in children, and similar effects are apparent in children suffering from Cushing's syndrome. 42 Thus, cortisol was a good candidate to test for effects on GHR gene expression.
In this study, we examined the effects of the synthetic glucocorticoid Dex on human adipocytes and found biphasic effects on both GHR mRNA expression and the GHR promoter constructs: a significant upregulation at 10 À10 and 10 À8 M concentrations, followed by a decline at higher doses.
Similar dose-dependent biphasic effects of glucocorticoids on GHR expression have been shown previously in studies of various different cell types, including human chondrocytes 43 and rat hepatocytes. 40 Our study is the first to show that Dex can influence GHR expression in mature human adipocytes in a dose-dependent manner and to suggest that these effects are mediated by the direct association of glucocorticoid receptor to a GRE situated on one of the GHR gene promoters. Interestingly, Paulsen et al. 44 have reported that GH treatment of GH-deficient adults results in decreased 11b-HSD1 and increased 11b-HSD2 in their subcutaneous fat depots, suggesting that GH is normally able to reduce the amount of locally produced cortisol in the adipose tissue. In the obese state, with lower GHR expression in the adipocytes, this ability may be compromised, contributing to the increase in intracellular cortisol concentrations.
Conclusions
In this study, we have shown that at least three obesityassociated factors, namely TNFa, HIF-1a and glucocorticoids, can regulate GHR expression in human adipocytes and HEK293 cells. Of these factors, TNFa clearly causes a significant suppression of GHR mRNA production, whereas HIF-1a stimulates GHR expression. However, when cells are treated with both TNFa and a hypoxia mimetic, the suppressive effects of TNFa on GHR expression are predominant, suggesting that TNFa may have an important role in downregulating GHR expression in obesity. Glucocorticoids have a biphasic effect on GHR expression as expected. This suggests that, as intracellular glucocorticoid levels increase in obese adipocytes, their stimulatory effects may be lost. Therefore, together with TNFa, glucocorticoids may also contribute to GHR suppression in the adipose tissues of obese individuals. 
